GREFFEX USA

Genetic Engineering

Global genetic engineering company with 20 years’ experience.

  • Healthcare
  • STO
  • Genetic Engineering
Fundraising goal:

20.000.000 EUR

Elevator pitch

Greffex Inc. is a leader in the global genetic engineering field with 20 years’ experience, headquartered in Houston, Texas with its laboratories in Aurora, Colorado. The company offers solutions to treat genetic disorders, eradicate rejection in organ transplantation and prevent viral diseases.

Jhon R. Price, CEO Greffex Inc.

Highlights

  • Since its foundation, Greffex Inc. has raised USD 23.2 MM
  • The FDA has agreed to Greffex’s accelerated clinical trial path with an expected first sale of Avian Flu (H5N1)
  • The Company has a valuable portfolio of patents (12 awarded patents and 9 patents pending) protecting its platform IP
  • Greffex has developed 12 vaccines – H5N1, H7N9, Anthrax, Covid-19, and others
  • The Company is preparing to enter clinical trials for Avian Flu (H5N1), under a contract valued at up to $18.9million with the US National Institute for Health (NIH)).
  • Neil Bush has recently joined the Advisory board of the company

Team

  • CEO, Co-Founder
    Jhon R. Price

    • +35 years in management
    • Former partner at Deloitte
    • Former COO at Goran Capital

  • Chief Scientific Officer
    Uwe D. Staerz

    • M.D, PhD in Molecular Biology at UC
    • Member of NIH committees
    Executive Vice President

  • Executive Vice President
    Willian Connolly

    • +20 years at JP Morgan
    • Former managing director at Societe Generale
    Executive Vice President

  • Executive Vice President
    Judge Robert Eckels

    • Chairman of the Texas County & District Retirement System, at USD 34 billion
    • Years of executive and board experience

Fundraising Goal

Investment Goal
  • Clinical trials
  • Team Expansion
  • New Therapeutics Development
Investment Goal

Company Overview

Founded in 2005, Greffex has created the most versatile gene delivery vehicle with broad applications in vaccination, gene therapy and tissue engineering. The company is headquartered in Houston, Texas with its laboratories in Aurora, Colorado.
Through his platform Greffex Inc. develop different solutions to protect people from viral infections, prevent and cure genetic disorders and eliminate rejection in organ transplants.

Greffex Background

Since its foundation, Greffex Inc. has raised USD 23.2 MM
The Company has a valuable portfolio of patents (12 awarded patents and 9 patents pending) protecting its platform IP
The Company is preparing to enter clinical trials for Avian Flu (H5N1), under a contract valued at up to $18.9million with the US National Institute for Health (NIH)).
Greffex has developed 12 vaccines – H5N1, H7N9, Anthrax, Covid-19, and others
The FDA has agreed to Greffex’s accelerated clinical trial path with an expected first sale of Avian Flu (H5N1)

The Offering

Greffex is offering a Series STO Convertible Preferred Stock (trough an STO) which shall accrue dividends at the rate of eight percent and convertible into 3,600 shares of Common Stock. The amount currently being raised is 20 million.

Traction & Numbers

The company was awarded with a USD 18 million dollars contract in 2019 to develop a vaccine for the H5N1 virus. The technology has been validated by the NIH in the USA.
Up to date, Greffex has already developed a vaccine for the Covid-19, which started Clinical Trials.
Greffex’s pipeline includes 12 other vaccines: influenza, MERS-CoV, Anthrax, Ebola, tetravalent Dengue and Zika
The company counts with a highly experienced team of professionals, including Mr. Nail Bush as part of the board
A pre purchase LOI for 50M vaccine doses has already been signed with one of the governments in Latin America.

More details about the company can be found on the website http://www.greffex.com/
Or from:
– The Washington Times https://www.washingtontimes.com/news/2020/feb/21/report-houston-company-says-it-developed-coronavir/
– Fox News https://www.foxnews.com/media/john-price-coronavirus-vaccine-greffex
-Cision https://www.prweb.com/releases/greffex_inc_completes_covid_19_vaccine_and_prepares_for_testing/prweb16971219.htm